Institutional investors purchased a net $4.4 million shares of AEGR during the quarter ended June 2016 and now own 88.94% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BROADFIN CAPITAL LLC Bought 351.0 Thousand shares of Aegerion Pharmaceuticals ...
FNY CAPITAL MANAGEMENT LP Bought 29.0 Thousand shares of Aegerion Pharmaceuticals ...